Skip to content

King Pharmaceuticals KG General Liability — Year 3

Other product segments

Commercial Auto Liability
18.7%
European Hospital Liability
10.4%
All other lines
2.7%
International
2.7%

Similar metrics at other companies

CNA Financial logo
CNAGeneral Liability — Year 3
15.5%-0.2pp
Old Republic International logo
ORIGeneral Liability — Year 3
15.7%+0.6pp
The Hartford Financial Services Group logo
HIGGeneral Liability — 3rd Year
12%+0.2pp
CNA Financial logo
CNAGeneral Liability — Year 2
12.1%-0.4pp
CNA Financial logo
CNAGeneral Liability — Year 1
3.4%0.0pp
CNA Financial logo
CNAGeneral Liability — Year 4
16.6%-0.2pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearThree.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's general liability — year 3.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's general liability — year 3?
King Pharmaceuticals (KG) reported general liability — year 3 of 13.1% in Q4 2025.
What does general liability — year 3 mean?
This metric represents the third year of development for general liability claims, providing a more mature view of the loss experience for a specific policy cohort. It is essential for validating the accuracy of earlier reserve estimates and identifying long-term trends in claim costs.